Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and depletes pathological immune cells.
Location: United States
Total raised: $267M
Investors 3
| Date | Name | Website |
| 18.02.2022 | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| 23.03.2022 | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.10.2025 | Series C | $183M | Nextech In... |
| 17.02.2022 | Series B | $84M | - |
Mentions in press and media 8
| Date | Title | Description |
| 27.10.2025 | Electra Therapeutics Raises $183M Series C | SAN FRANCISCO, CA, Electra Therapeutics announces $183 million series C financing. >> Click here for more funding data on Electra Therapeutics >> To export Electra Therapeutics funding data to PDF and Excel, click here Electra ... |
| 22.10.2025 | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics Wed, Oct 22, 2025 13:10 CET Report this content Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with seriou... |
| 22.10.2025 | 'Some encouraging signs in the market': Electra shines with $183M fundraise for rare disease trial | Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech’s just-launched pivotal trial for its rare disease candidate. Nextech and EQT Life Sciences co-led the charge, with... |
| 22.10.2025 | Electra Therapeutics Raises $183M in Series C Funding | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, raised $183m in Series C financing. The round was co-led by Nextech... |
| 17.02.2022 | Electra Therapeutics Raises $84M in Series B Financing | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company, raised $84M in Series B funding. The round was led by Westlake Village BioPartners and OrbiMed with participation from Redmile Group, Cormorant Asse... |
| 16.02.2022 | Electra Therapeutics Announces $84M Series B | SOUTH SAN FRANCISCO, CA, Electra Therapeutics, a biotechnology company, raised a $84M Series B financing co-led by Westlake Village BioPartners and OrbiMed. >> Click here for more funding data on Electra Therapeutics >> To e... |
| 13.02.2022 | Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer | - |
| - | Electra Therapeutics | “ELECTRA Therapeutics” |